UNASSIGNED: The role of anti-epithelial growth factor receptor monoclonal antibodies (anti- @entity470 MoAbs) in treatment-related electrolyte disorders is still controversial. Therefore, we conducted a meta-analysis of published @entity23 ( @entity23 ) to evaluate the incidences and overall risks of all-grade and grade 3/4 electrolyte disorder events. We searched relevant clinical trials from PubMed, EMBASE, and Web of Knowledge databases, meeting proceedings of American Society of Clinical Oncology and the European Society of Medical Oncology, as well as ClinicalTrials.gov. Eligible studies included phases II, III, and IV @entity23 . Statistical analysis was performed to calculate the summary incidence, relative risk (RR), and 95  % confidence intervals (CIs) using fixed effects or random effects models based on the heterogeneity of included studies. A total of 16,411 @entity1 from 25 @entity23 were included in this meta-analysis. The all-grade incidence of @entity1272 related to anti- @entity470 MoAbs was 34.0  % (95  % CI 28.0-40.5  %), and that for @entity1371 and @entity3747 were 14.5  % (95  % CI 8.2-24.4  %) and 16.8  % (95  % CI 14.2-19.7  %), respectively. Compared with chemotherapy alone in @entity14 , addition of cetuximab increased the risk of grade 3/4 @entity1272 and grade 3/4 @entity1371 with RRs of 7.14 (95  % CI 3.13-16.27, p   <   0.001) and 2.19 (95  % CI 1.14-4.23, p   =   0.019). Additionally, @entity14 @entity1 in panitumumab cases were more vulnerable to grade 3/4 @entity1272 and @entity1371 (RR 18.29, 95  % CI 7.29-48.41, p   <   0.001, and RR 3.3, 95  % CI 1.32-8.25, p   =   0.011). Treatment with anti- @entity470 MoAbs is associated with significantly higher risks of electrolyte disorders such as @entity1272 , @entity1272 , and @entity3747 , especially in @entity14 . Rigorous monitoring and early treatment of electrolyte disorders are proposed.

Electrolyte disorders assessment in solid tumor @entity1 treated with anti- XXXX monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3747 :: ('MESH:D006996', 'Disease') :: ['hypocalcemia'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity1272 :: ('MESH:C537153', 'Disease') :: ['hypomagnesemia'] @entity23 :: ('MESH:D007174', 'Disease') :: ['randomized controlled trials', 'RCTs'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia']
@entity470 :: (1956,Gene) :: ['EGFR']
